Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
TOKYO, June 16, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that Astellas and Cheplapharm Arzneimittel GmbH (“Cheplapharm”) have enterd into an Asset Purchase Agreement, under which Astellas will...
TOKYO, June 8, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced the presentation of new data in acute myeloid leukemia (AML) at the European Hematology Association (EHA) virtual congress...
TOKYO, June 3, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas” ) is constantly reviewing its management resource allocation in order to respond flexibly to rapid changes in the business environment and strengthen...
Read more about Reviewing capabilities for sustainable growth
TOKYO, May 26, 2021 - Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced its new Corporate Strategic Plan 2021 (“CSP2021”) for fiscal years 2021 through 2025...
Read more about Astellas Announces New Corporate Strategic Plan 2021
TOKYO & BOTHELL, Wash. – May 19, 2021 – Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Seagen Inc. (Nasdaq:SGEN) today announced updated results from two clinical trials examining PADCEV® (enfortumab vedotin-ejfv)...
Follow us
